Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry

Molecular Pharmaceutics

Volumn 10, Issue 3, 2013, Pages 793-812

  Lo, Su Tang ^a   Kumar, Amit ^a   Hsieh, Jer Tsong ^b   Sun, Xiankai ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

dendrimer; drug delivery; molecular imaging; prostate cancer; theranostics

Indexed keywords

ACETYLCYSTEINE; CAMPTOTHECIN; CURCUMIN; DENDRIMER; DOXORUBICIN; GENISTEIN; IBUPROFEN; LUTETIUM 177; METHOTREXATE; MOLECULAR SCAFFOLD; NAPROXEN; PACLITAXEL; RESVERATROL; RITUXIMAB; TRASTUZUMAB;

CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; MOLECULAR IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; REVIEW;

EID: 84874619226     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp3005325     Document Type: Review

References (253)

1. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989, 244 (4905) 707-712
2. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimito, R. A.; Brannigan, B. A.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Loius, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 2004, 350 (21) 2129-2139
3. Paez, J. G.; Janne, P. A.; Lee, J. C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F. J.; Lindeman, N.; Boggon, T. J.; Naoko, K.; Sasaki, H.; Jujji, Y.; Eck, M. J.; Sellers, W. R.; Johnson, B. E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clininical response to gefitinib therapy Science 2004, 304 (5676) 1497-1500
4. Minna, J. D.; Gazdar, A.; Sprang, S. R.; Herz, J. Cancer. A bull's eye for targeted lung therapy Science 2004, 304 (5676) 1458-1461
5. Dancey, J. E. Predictive factors for epidermal growth factor receptor inhibitors- the bull's-eye hits the arrow Cancer Cell 2004, 5 (5) 411-415
6. Arteaga, C. L. Selecting the right patient for tumor therapy Nat. Med. 2004, 10 (6) 577-578
7. Janib, S. M.; Moses, A. S.; MacKay, J. A. Imaging and drug delivery using theranostic nanoparticles Adv. Drug Delivery Rev. 2010, 62 (11) 1052-1063
8. Lee, D. Y.; Li, K. C. Molecular theranostics: a primer for the imaging professional Am. J. Roentgenol. 2011, 197 (2) 318-324
9. Grayson, S. M.; Frechet, J. M. J. Convergent dendrons and dendrimers: from synthesis to applications Chem. Rev. 2001, 101 (12) 3819-3867
10. Lee, C. C.; MacKay, J. A.; Frechet, J. M. J.; Szoka, F. C. Designing dendrimers for biological applications Nat. Biotechnol. 2005, 23 (12) 1517-1526
11. Liu, M. J.; Frechet, J. M. J. Designing dendrimers for drug delivery Pharm. Sci. Technol. Today 1999, 2 (10) 393-401
12. Frechet, J. M. J. Functional polymers and dendrimers: reactivity, molecular architecture, and interfacial energy Science 1994, 263 (5154) 1710-1715
13. Svec, F.; Frechet, J. M. J. New designs of macroporous polymers and supports: From separation to biocatalysis Science 1996, 273 (5272) 205-211
14. Luo, Y.; Prestwich, G. D. Cancer-targeted polymeric drugs Curr. Cancer Drug Targets 2002, 2 (3) 209-226
15. Chen, Z.; Penet, M. F.; Nimmagadda, S.; Li, C.; Banerjee, S. R.; Winnard, P. T., Jr.; Artemov, D.; Glunde, K.; Pomper, M. G.; Bhujwalla, Z. M. PSMA-targeted theranostic nanoplex for prostate cancer therapy ACS Nano 2012, 6 (9) 7752-7762
16. Lukianova-Hleb, E. Y.; Oginsky, A. O.; Samaniego, A. P.; Shenefelt, D. L.; Wagner, D. S.; Hafner, J. H.; Farach-Carson, M. C.; Lapotko, D. O. Tunable plasmonic nanoprobes for theranostics of prostate cancer Theranostics 2011, 1, 3-17
17. Svenson, S.; Tomalia, D. A. Dendrimers in biomedical applications- reflections on the field Adv. Drug Delivery Rev. 2005, 57 (15) 2106-2129
18. Gillies, E. R.; Frechet, J. M. J. Dendrimers and dendritic polymers in drug delivery Drug Discovery Today 2005, 10 (1) 35-43
19. Fréchet, J. M. J.; Tomalia, D. A. Dendrimers and other dendritic polymers; Wiley: New York, 2001.
20. Ahmed, N.; Fessi, H.; Elaissari, A. Theranostic applications of nanoparticles in cancer Drug Discovery Today 2012, 17 (17-18) 928-934
21. Jokerst, J. V.; Gambhir, S. S. Molecular imaging with theranostic nanoparticles Acc. Chem. Res. 2011, 44 (10) 1050-1060
22. Ma, X.; Zhao, Y.; Liang, X. J. Theranostic nanoparticles engineered for clinic and pharmaceutics Acc. Chem. Res. 2011, 44 (10) 1114-1122
23. Menjoge, A. R.; Kannan, R. M.; Tomalia, D. A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications Drug Discovery Today 2010, 15 (5-6) 171-185
24. Rudin, M. Molecular imaging: principles and applications in biomedical research; Imperial College Press: London, UK, 2005.
25. Hahn, M. A.; Singh, A. K.; Sharma, P.; Brwon, S. C.; Moudgil, B. M. Nanoparticles as contrast agents for in-vivo bioimaging: current status and future perspectives Anal. Bioanal. Chem. 2011, 399 (1) 3-27
26. Debbage, P.; Jaschke, W. Molecular imaging with nanoparticles: giant roles for dwarf actors Histochem. Cell Biol. 2008, 130 (5) 845-875
27. Jin, M. H. G.; Sun, X.; Chen, W. Nanoparticle-based positron emission tomography and single photon emission computed tomography imaging of cancer Rev. Nanosci. Nanotechnol. 2012, 1 (19) 3-21
28. Kobayashi, H.; Sato, N.; Saga, T.; Nakamoto, Y.; Ishimori, T.; Toyama, S.; Togashi, K.; Konishi, J.; Brechbiel, M. W. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity Eur. J. Nucl. Med. 2000, 27 (9) 1334-1339
29. Wolinsky, J. B.; Grinstaff, M. W. Therapeutic and diagnostic applications of dendrimers for cancer treatment Adv. Drug Delivery Rev. 2008, 60 (9) 1037-1055
30. Nanjwade, B. K.; Bechra, H. M.; Derkar, G. K.; Manvi, F. V.; Nanjwade, V. K. Dendrimers: emerging polymers for drug-delivery systems Eur. J. Pharm. Sci. 2009, 38 (3) 185-196
31. Fuchs, S.; Kapp, T.; Otto, H.; Schöneberg, T.; Franke, P.; Gust, R.; Schlüter, A. D. A surface-modified dendrimer set for potential application as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization Chem.-Eur. J. 2004, 10 (5) 1167-1192
32. Jones, S. P.; Gabrielson, N. P.; Pack, D. W.; Smith, D. K. Synergistic effects in gene delivery-a structure-activity approach to the optimization of hybrid dendritic-lipidic transfection agents Chem. Commun. 2008, 39, 4700-4702
33. Berna, M.; Dalzoppo, D.; Pasut, G.; Manunta, M.; Izzo, L.; Jones, A. T.; Duncan, R.; Veronese, F. M. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake Biomacromolecules 2005, 7 (1) 146-153
34. Reul, R.; Renette, T.; Bege, N.; Kissel, T. Nanoparticles for paclitaxel delivery: A comparative study of different types of dendritic polyesters and their degradation behavior Int. J. Pharmaceutics 2011, 407 (1-2) 190-196
35. Langereis, S.; de Lussanet, Q. G.; van Genderen, M. H. P.; Meijer, E. W.; Beets-Tan, R. G. H.; Griffioen, A. W.; van Engelshoven, J. M. A.; Backes, W. H. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging NMR Biomed. 2006, 19 (1) 133-141
36. Rolland, O.; Turrin, C.-O.; Caminade, A.-M.; Majoral, J.-P. Dendrimers and nanomedicine: multivalency in action New J. Chem. 2009, 33 (9) 1809-1824
37. Paleos, C. M.; Tsiourvas, D.; Sideratou, Z.; Tziveleka, L.-A. Drug delivery using multifunctional dendrimers and hyperbranched polymers Exp. Opin. Drug Delivery 2010, 7 (12) 1387-1398
38. Chabre, Y. M.; Roy, R. Recent trends in glycodendrimer syntheses and applications Curr. Top. Med. Chem. 2008, 8 (14) 1237-1285
39. Garner, A. L.; Park, J.; Zakhari, J. S.; Lowery, C. A.; Struss, A. K.; Sawada, D.; Kaufmann, G. F.; Janda, K. D. A multivalent probe for AI-2 quorum-sensing receptors J. Am. Chem. Soc. 2011, 133 (40) 15934-15937
40. Schlick, K. H.; Udelhoven, R. A.; Strohniever, G. C.; Cloninger, M. J. Binding of mannose-functionalized dendrimers with pea (Pisum sativum) lectin Mol. Pharmaceutics 2005, 2 (4) 295-301
41. Maheshwari, G.; Brown, G.; Lauffenburger, D. A.; Wells, A.; Griffith, L. G. Cell adhesion and motility depend on nanoscale RGD clustering J. Cell Sci. 2000, 113 (10) 1677-1686
42. Fuki, I. V.; Kuhn, K. M.; Lomazov, I. R.; Rothman, V. L.; Tuszynski, G. P.; Iozzo, R. V.; Swenson, T. L.; Fisher, E. A.; Williams, K. J. The syndecan family of proteoglycans-Novel receptors mediating internalization of atherogenic lipoproteins in vitro J. Clin. Invest. 1997, 100 (6) 1611-1622
43. Schlick, K. H.; Morgan, J. R.; Weiel, J. J.; Kelsey, M. S.; Cloninger, M. J. Clusters of ligands on dendrimer surfaces Bioorg. Med. Chem. Lett. 2011, 21 (17) 5078-5083
44. Venkataraman, S.; Hedrick, J. L.; Ong, Z. Y.; Yang, C.; Ee, P. L. R.; Hammond, P. T.; Yang, Y. Y. The effects of polymeric nanostructure shape on drug delivery Adv. Drug Delivery Rev. 2011, 63 (14-15) 1228-1246
45. Jansen, J. F. G. A.; de Brabander-van den Berg, E. M. M.; Meijer, E. W. Encapsulation of guest molecules into a dendritic box Science 1994, 266 (5188) 1226-1229
46. van Hest, J. C. M.; Delnoye, D. A. P.; Baars, M. W. P. L.; van Genderen, M. H. P.; Meijer, E. W. Polystyrene-dendrimer amphiphilic block copolymers with a generation-dependent aggregation Science 1995, 268 (5217) 1592-1595
47. Kirkpatrick, G. J.; Plumb, J. A.; Sutcliffe, O. B.; Flint, D. J.; Wheate, N. J. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin J. Inorg. Biochem. 2011, 105 (9) 1115-1122
48. Tziveleka, L.-A.; Kontoyianni, C.; Sideratou, Z.; Tsiourvas, D.; Paleos, C. M. Novel Functional Hyperbranched Polyether Polyols as Prospective Drug Delivery Systems Macromol. Biosci. 2006, 6 (2) 161-169
49. Paleos, C. M.; Tsiourvas, D.; Sideratou, Z.; Tziveleka, L. Acid- and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system Biomacromolecules 2004, 5 (2) 524-529
50. Sideratou, Z.; Sterioti, N.; Tsiourvas, D.; Tziveleka, L.-A.; Thanassoulas, A.; Nounesis, G.; Paleos, C. M. Arginine end-functionalized poly(l-lysine) dendrigrafts for the stabilization and controlled release of insulin J. Colloid Interface Sci. 2010, 351 (2) 433-441
51. Kono, K.; Kojima, C.; Hayashi, N.; Nishisaka, E.; Kiura, K.; Wataral, S.; Harada, A. Preparation and cytotoxic activity of poly(ethylene glycol)-modified poly(amidoamine) dendrimers bearing adriamycin Biomaterials 2008, 29 (11) 1664-1675
52. Kurtoglu, Y. E.; Mishra, M. K.; Kannan, S.; Kannan, R. M. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers Int. J. Pharmaceutics 2010, 384 (1-2) 189-194
53. Chang, Y. L.; Liu, N. A.; Chen, L.; Meng, X. L.; Liu, Y. J.; Li, Y. P.; Wang, J. Y. Synthesis and characterization of DOX-conjugated dendrimer-modified magnetic iron oxide conjugates for magnetic resonance imaging, targeting, and drug delivery J. Mater. Chem. 2012, 22 (19) 9594-9601
54. Agarwal, A.; Gupta, U.; Asthana, A.; Jain, N. K. Dextran conjugated dendritic nanoconstructs as potential vectors for anti-cancer agent Biomaterials 2009, 30 (21) 3588-3596
55. Lee, C. C.; Gillies, E. R.; Fox, M. E.; Guillaudeu, S. J.; Fréchet, J. M. J.; Dy, E. E.; Szoka, F. C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (45) 16649-16654
56. Lim, J.; Chouai, A.; Lo, S. T.; Liu, W.; Sun, X.; Simanek, E. E. Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages Bioconjugate Chem. 2009, 20 (11) 2154-2161
57. Roller, S.; Zhou, H.; Haag, R. High-loading polyglycerol supported reagents for Mitsunobu- and acylation-reactions and other useful polyglycerol derivatives Mol. Divers. 2005, 9 (4) 305-316
58. Seebach, D.; Herrmann, G. F.; Lengweiler, U. D.; Bachmann, B. M.; Amrein, W. Synthesis and Enzymatic Degradation of Dendrimers from (R)-3-Hydroxybutanoic Acid and Trimesic Acid Angew. Chem., Int. Ed. Engl. 1996, 35 (23-24) 2795-2797
59. Kolhe, P.; Khandare, J.; Pillai, O.; Kannan, S.; Lieh-Lal, M.; Kannan, R. M. Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload Biomaterials 2006, 27 (4) 660-669
60. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery Int. J. Pharmaceutics 2007, 336 (1) 183-190
61. Quintana, A.; Raczka, E.; Piehler, L.; Lee, I.; Myc, A.; Majoros, I.; Patri, A. K.; Thomas, T.; Mule, J.; Baker, J. R. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor Pharm. Res. 2002, 19 (9) 1310-1316
62. Thomas, T. P.; Majoros, I. J.; Kotlyar, A.; Kukowska-Latallo, J. F.; Bielinska, A.; Myc, A.; Baker, J. R. Targeting and inhibition of cell growth by an engineered dendritic nanodevice J. Med. Chem. 2005, 48 (11) 3729-3735
63. Kale, A. A.; Torchilin, V. P. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates Bioconjugate Chem. 2007, 18 (2) 363-370
64. Shen, W. C.; Ryser, H. J. cis-Aconityl spacer between daunomycin and macromolecular carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate Biochem. Biophys. Res. Commun. 1981, 102 (3) 1048-1054
65. Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style Biomaterials 2010, 31 (6) 1360-1371
66. Gilbert, H. F. Thiol/disulfide exchange equilibria and disulfidebond stability. In Methods in Enzymology; Lester, P., Ed.; Academic Press: New York, 1995; Vol. 251, pp 8-28.
67. Meister, A.; Anderson, M. E. Glutathione Annu. Rev. Biochem. 1983, 52 (1) 711-760
68. Russo, A.; DeGraff, W.; Friedman, N.; Mitchell, J. B. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs Cancer Res. 1986, 46 (6) 2845-2848
69. Navath, R. S.; Kurtoglu, Y. E.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels Bioconjugate Chem. 2008, 19 (12) 2446-2455
70. Wang, B.; Navath, R. S.; Romero, R.; Kannan, S.; Kannan, R. Anti-inflammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells Int. J. Pharmaceutics 2009, 377 (1-2) 159-168
71. Kurtoglu, Y. E.; Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery Biomaterials 2009, 30 (11) 2112-2121
72. Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Stimuli-responsive star poly(ethylene glycol) drug conjugates for improved intracellular delivery of the drug in neuroinflammation J. Controlled Release 2010, 142 (3) 447-456
73. Lim, J.; Lo, S. T.; Hill, S.; Pavan, G. M.; Sun, X.; Simanek, E. E. Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers Mol. Pharmaceutics 2012, 9 (3) 404-412
74. Lo, S. T.; Stern, S.; Clogston, J. D.; Zheng, J.; Adiseshaiah, P. P.; Dobrovolskaia, M.; Lim, J.; Patri, A. K.; Sun, X.; Simanek, E. E. Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct Mol. Pharmaceutics 2010, 7 (4) 993-1006
75. Mullen, D. G.; Fang, M.; Desai, A.; Baker, J. R.; Orr, B. G.; Banaszak Holl, M. M. A Quantitative assessment of nanoparticle-ligand distributions: implications for targeted drug and imaging delivery in dendrimer conjugates ACS Nano 2010, 4 (2) 657-670
76. Mullen, D. G.; Borgmeier, E. L.; Desai, A. M.; van Dongen, M. A.; Barash, M.; Cheng, X. M.; Baker, J. R.; Holl, M. M. B. Isolation and characterization of dendrimers with precise numbers of functional groups Chem.-Eur. J. 2010, 16 (35) 10675-10678
77. Hakem, I. F.; Leech, A. M.; Johnson, J. D.; Donahue, S. J.; Walker, J. P.; Bockstaller, M. R. Understanding ligand distributions in modified particle and particlelike systems J. Am. Chem. Soc. 2010, 132 (46) 16593-16598
78. Ornelas, C.; Pennell, R.; Liebes, L. F.; Weck, M. Construction of a well-defined multifunctional dendrimer for theranostics Org. Lett. 2011, 13 (5) 976-979
79. Sapsford, K. E.; Tyner, K. M.; Dair, B. J.; Deschamps, J. R.; Medintz, I. L. Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques Anal. Chem. 2011, 83 (12) 4453-4488
80. Mullen, D. G.; Holl, M. M. B. Heterogeneous ligand-nanoparticle distributions: a major obstacle to scientific understanding and commercial translation Acc. Chem. Res. 2011, 44 (11) 1135-1145
81. Zong, H.; Thomas, T. P.; Lee, K. H.; Desai, A. M.; Li, M. H.; Kotlyar, A.; Zhang, Y. H.; Leroueil, P. R.; Gam, J. J.; Holl, M. M. B.; Baker, J. R. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio Biomacromolecules 2012, 13 (4) 982-991
82. Mullen, D. G.; Desai, A.; van Dongen, M. A.; Barash, M.; Baker, J. R.; Banaszak Holl, M. M. Best practices for purification and characterization of PAMAM dendrimer Macromolecules 2012, 45 (12) 5316-5320
83. Thomas, T. P.; Huang, B.; Choi, S. K.; Silpe, J. E.; Kotlyar, A.; Desai, A. M.; Zong, H.; Gam, J.; Joice, M.; Baker, J. R. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic Mol. Pharmaceutics 2012, 9 (9) 2669-2676
84. Karthikeyan, B. K. P. V. Prednisolone conjugated polypropylene imine dendritic architecture confers. reducing hemolytic toxicity- a comparative study Int. J. Drug Dev. Res. 2012, 4 (2) 188-194
85. Roberts, J. C.; Bhalgat, M. K.; Zera, R. T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers J. Biomed. Mater. Res. 1996, 30 (1) 53-65
86. 125I-labelled polyamidoamine dendrimers in vivo J. Controlled Release 2000, 65 (1-2) 133-148
87. Najlah, M.; Freeman, S.; Attwood, D.; D'Emanuele, A. In vitro evaluation of dendrimer prodrugs for oral drug delivery Int. J. Pharmaceutics 2007, 336 (1) 183-190
88. Kolhatkar, R. B.; Kitchens, K. M.; Swaan, P. W.; Ghandehari, H. Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability Bioconjugate Chem. 2007, 18 (6) 2054-2060
89. Sadekar, S.; Ghandehari, H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery Adv. Drug Delivery Rev. 2012, 64 (6) 571-588
90. Yang, H.; Lopina, S. T.; DiPersio, L. P.; Schmidt, S. P. Stealth dendrimers for drug delivery: correlation between PEGylation, cytocompatibility, and drug payload J. Mater. Sci. Mater. Med. 2008, 19 (5) 1991-1997
91. Tang, Y.; Li, Y. B.; Wang, B.; Lin, R. Y.; van Dongen, M.; Zurcher, D. M.; Gu, X. Y.; Banaszak Holl, M. M.; Liu, G.; Qi, R. Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers Mol. Pharmaceutics 2012, 9 (6) 1812-1821
92. Aungst, B. J. Intestinal permeation enhancers J. Pharm. Sci. 2000, 89 (4) 429-442
93. Jevprasesphant, R.; Penny, J.; Jalal, R.; Attwood, D.; McKeown, N. B.; D'Emanuele, A. The influence of surface modification on the cytotoxicity of PAMAM dendrimers Int. J. Pharmaceutics 2003, 252 (1-2) 263-266
94. Thanou, M.; Duncan, R. Polymer-protein and polymer-drug conjugates in cancer therapy Curr. Opin. Invest. Drugs 2003, 4 (6) 701-709
95. Duncan, R. The dawning era of polymer therapeutics Nat. Rev. Drug Discovery 2003, 2 (5) 347-360
96. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46 (12 Pt 1) 6387-6392
97. Munn, L. L. Aberrant vascular architecture in tumors and its importance in drug-based therapies Drug Discovery Today 2003, 8 (9) 396-403
98. Hobbs, S. K.; Monsky, W. L.; Yuan, F.; Roberts, W. G.; Griffith, L.; Torchilin, V. P.; Jain, R. K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (8) 4607-4612
99. Padera, T. P.; Kadambi, A.; di Tomaso, E.; Carreira, C. M.; Brown, E. B.; Boucher, Y.; Choi, N. C.; Mathisen, D.; Wain, J.; Mark, E. J.; Munn, L. L.; Jain, R. K. Lymphatic metastasis in the absence of functional intratumor lymphatics Science 2002, 296 (5574) 1883-1886
100. Brannon-Peppas, L.; Blanchette, J. O. Nanoparticle and targeted systems for cancer therapy Adv. Drug Delivery Rev. 2004, 56 (11) 1649-1659
101. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis Adv. Drug Delivery Rev. 2002, 54 (5) 631-651
102. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation J. Nucl. Med. 2005, 46 (7) 1210-1218
103. Dubey, P. K.; Mishra, V.; Jain, S.; Mahor, S.; Vyas, S. P. Liposomes modified with cyclic RGD peptide for tumor targeting J. Drug Target. 2004, 12 (5) 257-264
104. Guccione, S.; Li, K. C.; Bednarski, M. D. Vascular-targeted nanoparticles for molecular imaging and therapy Methods Enzymol. 2004, 386, 219-236
105. Hood, J. D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R. A.; Xiang, R.; Cheresh, D. A. Tumor regression by targeted gene delivery to the neovasculature Science 2002, 296 (5577) 2404-2407
106. Li, Y.; Tseng, Y. D.; Kwon, S. Y.; d'Espaux, L.; Bunch, J. S.; McEuen, P. L.; Luo, D. Controlled assembly of dendrimer-like DNA Nat. Mater. 2004, 3 (1) 38-42
107. 3-targeted nanoparticle and 1.5 T magnetic resonance imaging Cancer Res. 2003, 63 (18) 5838-5843
108. Israeli, R. S.; Powell, C. T.; Corr, J. G.; Fair, W. R.; Heston, W. D. Expression of the prostate-specific membrane antigen Cancer Res. 1994, 54 (7) 1807-1811
109. Bostwick, D. G.; Pacelli, A.; Blute, M.; Roche, P.; Murphy, G. P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases Cancer 1998, 82 (11) 2256-2261
110. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell. Biochem. 2004, 91 (3) 528-539
111. Huang, X.; Bennett, M.; Thorpe, P. E. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen Prostate 2004, 61 (1) 1-11
112. Lamb, H. M.; Faulds, D. Capromab pendetide. A review of its use as an imaging agent in prostate cancer Drug Aging 1998, 12 (4) 293-304
113. Gong, M. C.; Chang, S. S.; Watt, F.; O'Keefe, D. S.; Bacich, D. J.; Uchida, A.; Bander, N. H.; Reuter, V. E.; Gaudin, P. B.; Molloy, P. L.; Sadelian, M.; Heston, W. D. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy Mol. Urol. 2000, 4 (3) 217-222
114. Chang, S. S. Monoclonal antibodies and prostate-specific membrane antigen Curr. Opin. Invest. Drugs 2004, 5 (6) 611-615
115. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res. 1999, 59 (13) 3192-3198
116. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. H. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res. 1997, 57 (17) 3629-3634
117. Murphy, G. P.; Greene, T. G.; Tino, W. T.; Boynton, A. L.; Holmes, E. H. Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen J. Urol. 1998, 160 (6 Pt 2) 2396-2401
118. Smith-Jones, P. M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S. J.; Bander, N. H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor J. Nucl. Med. 2003, 44 (4) 610-617
119. Patri, A. K.; Myc, A.; Beals, J.; Thomas, T. P.; Bander, N. H.; Baker, J. R. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy Bioconjugate Chem. 2004, 15 (6) 1174-1181
120. Brody, E. N.; Gold, L. Aptamers as therapeutic and diagnostic agents J. Biotechnol. 2000, 74 (1) 5-13
121. Brody, E. N.; Willis, M. C.; Smith, J. D.; Jayasena, S.; Zichi, D.; Gold, L. The use of aptamers in large arrays for molecular diagnostics Mol. Diagn. 1999, 4 (4) 381-388
122. Ellington, A. D.; Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands Nature 1990, 346 (6287) 818-822
123. Ellington, A. D.; Szostak, J. W. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures Nature 1992, 355 (6363) 850-852
124. Gander, T. R.; Brody, E. N.; Mehler, R. E.; Heilig, J. S.; Singer, B. S.; Gold, L. Driving forces in cancer diagnostics Med. Lab. Obs. 2003, 35 (1) 10-16
125. Gold, L.; Singer, B.; He, Y. Y.; Brody, E. SELEX and the evolution of genomes Curr. Opin. Genet. Dev. 1997, 7 (6) 848-851
126. Irvine, D.; Tuerk, C.; Gold, L. SELEXION. Systematic evolution of ligands by exponential enrichment with integrated optimization by non-linear analysis J. Mol. Biol. 1991, 222 (3) 739-761
127. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase Science 1990, 249 (4968) 505-510
128. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells Cancer Res. 2004, 64 (21) 7668-7672
129. Lee, I. H.; An, S.; Yu, M. K.; Kwon, H. K.; Im, S. H.; Jon, S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates J. Controlled Release 2011, 155 (3) 435-441
130. Wu, X.; Ding, B.; Gao, J.; Wang, H.; Fan, W.; Wang, X.; Zhang, W.; Wang, X.; Ye, L.; Zhang, M.; Ding, X.; Liu, J.; Zhu, Q.; Gao, S. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy Int. J. Nanomed. 2011, 6, 1747-1756
131. Almushayt, A.; Narayanan, K.; Zaki, A. E.; George, A. Dentin matrix protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts Gene Ther. 2006, 13 (7) 611-620
132. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels Cell 1994, 79 (7) 1157-1164
133. Brakebusch, C.; Bouvard, D.; Stanchi, F.; Sakai, T.; Fassler, R. Integrins in invasive growth J. Clin. Invest. 2002, 109 (8) 999-1006
134. 3 for angiogenesis Science 1994, 264 (5158) 569-571
135. O'Reilly, M. S.; Boehm, T.; Shing, Y.; Fukai, N.; Vasios, G.; Lane, W. S.; Flynn, E.; Birkhead, J. R.; Olsen, B. R.; Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 1997, 88 (2) 277-85
136. Storgard, C. M.; Stupack, D. G.; Jonczyk, A.; Goodman, S. L.; Fox, R. I.; Cheresh, D. A. Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist J. Clin. Invest. 1999, 103 (1) 47-54
137. Weidner, N.; Semple, J. P.; Welch, W. R.; Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N. Engl. J. Med. 1991, 324 (1) 1-8
138. Bogdanowich-Knipp, S. J.; Chakrabarti, S.; Williams, T. D.; Dillman, R. K.; Siahaan, T. J. Solution stability of linear vs. cyclic RGD peptides J. Pept. Res. 1999, 53 (5) 530-541
139. Bogdanowich-Knipp, S. J.; Jois, D. S.; Siahaan, T. J. The effect of conformation on the solution stability of linear vs. cyclic RGD peptides J. Pept. Res. 1999, 53 (5) 523-529
140. Bogdanowich-Knipp, S. J.; Jois, S. D.; Siahaan, T. J. Effect of conformation on the conversion of cyclo-(1,7)-Gly-Arg-Gly-Asp-Ser-Pro-Asp-Gly-OH to its cyclic imide degradation product J. Pept. Res. 1999, 54 (1) 43-53
141. Hill, E.; Shukla, R.; Park, S. S.; Baker, J. R., Jr. Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures Bioconjugate Chem. 2007, 18 (6) 1756-1762
142. Shukla, R.; Thomas, T. P.; Peters, J.; Kotlyar, A.; Myc, A.; Baker, J. R., Jr. Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates Chem. Commun. (Cambridge) 2005, 46, 5739-5741
143. Wen, X.; Jackson, E. F.; Price, R. E.; Kim, E. E.; Wu, Q.; Wallace, S.; Charnsangavej, C.; Gelovani, J. G.; Li, C. Synthesis and characterization of poly(L-glutamic acid) gadolinium chelate: a new biodegradable MRI contrast agent Bioconjugate Chem. 2004, 15 (6) 1408-1415
144. 3+-loaded polyamidoamine and hyperbranched dendrimers J. Biol. Inorg. Chem. 2007, 12 (3) 406-420
145. Kobayashi, H.; Kawamoto, S.; Saga, T.; Sato, N.; Hiraga, A.; Ishimori, T.; Konishi, J.; Togashi, K.; Brechbiel, M. W. Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents Magn. Reson. Med. 2001, 46 (4) 781-788
146. Kiessling, F.; Morgenstern, B.; Zhang, C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging Curr. Med. Chem. 2007, 14 (1) 77-91
147. Bulte, J. W.; Douglas, T.; Witwer, B.; Zhang, S. C.; Strable, E.; Lewis, B. K.; Zywicke, H.; Miller, B.; van Gelderen, P.; Moskowitz, B. M.; Duncan, I. D.; Frank, J. A. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells Nat. Biotechnol. 2001, 19 (12) 1141-1147
148. Scherer, F.; Anton, M.; Schillinger, U.; Henke, J.; Bergemann, C.; Kruger, A.; Gansbacher, B.; Plank, C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo Gene Ther. 2002, 9 (2) 102-109
149. Liu, W. M.; Xue, Y. N.; He, W. T.; Zhuo, R. X.; Huang, S. W. Dendrimer modified magnetic iron oxide nanoparticle/DNA/PEI ternary complexes: a novel strategy for magnetofection J. Controlled Release 2011, 152 (Suppl. 1) e159-160
150. Xu, R.; Wang, Y.; Wang, X.; Jeong, E. K.; Parker, D. L.; Lu, Z. R. In vivo evaluation of a PAMAM-cystamine-(Gd-DO3A) conjugate as a biodegradable macromolecular MRI contrast agent Exp. Biol. Med. (Maywood) 2007, 232 (8) 1081-1089
151. Kobayashi, H.; Shirakawa, K.; Kawamoto, S.; Saga, T.; Sato, N.; Hiraga, A.; Watanabe, I.; Heike, Y.; Togashi, K.; Konishi, J.; Brechbiel, M. W.; Wakasugi, H. Rapid accumulation and internalization of radiolabeled herceptin in an inflammatory breast cancer xenograft with vasculogenic mimicry predicted by the contrast-enhanced dynamic MRI with the macromolecular contrast agent G6-(1B4M-Gd)(256) Cancer Res. 2002, 62 (3) 860-866
152. Talanov, V. S.; Regino, C. A.; Kobayashi, H.; Bernardo, M.; Choyke, P. L.; Brechbiel, M. W. Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging Nano Lett. 2006, 6 (7) 1459-1463
153. Kobayashi, H.; Kawamoto, S.; Sakai, Y.; Choyke, P. L.; Star, R. A.; Brechbiel, M. W.; Sato, N.; Tagaya, Y.; Morris, J. C.; Waldmann, T. A. Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent J. Natl. Cancer Inst. 2004, 96 (9) 703-708
154. Fu, Y.; Nitecki, D. E.; Maltby, D.; Simon, G. H.; Berejnoi, K.; Raatschen, H. J.; Yeh, B. M.; Shames, D. M.; Brasch, R. C. Dendritic iodinated contrast agents with PEG-cores for CT imaging: synthesis and preliminary characterization Bioconjugate Chem. 2006, 17 (4) 1043-1056
155. Ntziachristos, V.; Ripoll, J.; Wang, L. H. V.; Weissleder, R. Looking and listening to light: the evolution of whole-body photonic imaging Nat. Biotechnol. 2005, 23 (3) 313-320
156. Arridge, S. R. Optical tomography in medical imaging Inverse Probl. 1999, 15 (2) R41-R93
157. Konig, K. Multiphoton microscopy in life sciences J. Microsc. (Oxford) 2000, 200, 83-104
158. Villringer, A.; Chance, B. Non-invasive optical spectroscopy and imaging of human brain function Trends Neurosci. 1997, 20 (10) 435-442
159. Efimov, I. R.; Nikolski, V. P.; Salama, G. Optical imaging of the heart Circ. Res. 2004, 95 (1) 21-33
160. Ballou, B.; Ernst, L. A.; Waggoner, A. S. Fluorescence imaging of tumors in vivo Curr. Med. Chem. 2005, 12 (7) 795-805
161. Citrin, D.; Camphausen, K. Optical imaging of mice in oncologic research Exp. Rev. Anticancer Ther. 2004, 4 (5) 857-864
162. Kosaka, N.; Ogawa, M.; Choyke, P. L.; Kobayashi, H. Clinical implications of near-infrared fluorescence imaging in cancer Future Oncol. 2009, 5 (9) 1501-1511
163. Licha, K.; Olbrich, C. Optical imaging in drug discovery and diagnostic applications Adv. Drug Delivery Rev. 2005, 57 (8) 1087-1108
164. McDonald, D. M.; Choyke, P. L. Imaging of angiogenesis: from microscope to clinic Nat. Med. 2003, 9 (6) 713-725
165. Rao, J.; Dragulescu-Andrasi, A.; Yao, H. Fluorescence imaging in vivo: recent advances Curr. Opin. Biotechnol. 2007, 18 (1) 17-25
166. Koyama, Y.; Talanov, V. S.; Bernardo, M.; Hama, Y.; Regino, C. A. S.; Brechbiel, M. W.; Choyke, P. L.; Kobayashi, H. A dendrimer-based nanosized contrast agent, dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice J. Magn. Reson. Imaging 2007, 25 (4) 866-871
167. Kobayashi, H.; Koyama, Y.; Barrett, T.; Hama, Y.; Regino, C. A. S.; Shin, I. S.; Jang, B.-S.; Le, N.; Paik, C. H.; Choyke, P. L.; Urano, Y. Multimodal nanoprobes for radionuclide and five-color near-infrared optical lymphatic imaging ACS Nano 2007, 1 (4) 258-264
168. Yan, H.; Wang, J.; Yi, P.; Lei, H.; Zhan, C.; Xie, C.; Feng, L.; Qian, J.; Zhu, J.; Lu, W.; Li, C. Imaging brain tumor by dendrimer-based optical/paramagnetic nanoprobe across the blood-brain barrier Chem. Commun. (Cambridge) 2011, 47 (28) 8130-8132
169. Phelps, M. E. PET: The merging of biology and imaging into molecular imaging J. Nucl. Med. 2000, 41 (4) 661-681
170. Massoud, T. F.; Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light Gene. Dev. 2003, 17 (5) 545-580
171. Boswell, C. A.; Sun, X. K.; Niu, W. J.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J. Med. Chem. 2004, 47 (6) 1465-1474
172. Jones-Wilson, T. M.; Deal, K. A.; Anderson, C. J.; McCarthy, D. W.; Kovacs, Z.; Motekaitis, R. J.; Sherry, A. D.; Martell, A. E.; Welch, M. J. The in vivo behavior of copper-64-labeled azamacrocyclic complexes Nucl. Med. Biol. 1998, 25 (6) 523-530
173. Wu, C. C.; Jagoda, E.; Brechbiel, M.; Webber, K. O.; Pastan, I.; Gansow, O.; Eckelman, W. C. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment Bioconjugate Chem. 1997, 8 (3) 365-369
174. Prata, M. I. M.; Santos, A. C.; Geraldes, C.; de Lima, J. J. P. Structural and in vivo studies of metal chelates of Ga(III) relevant to biomedical imaging J. Inorg. Biochem. 2000, 79 (1-4) 359-363
175. Li, Z. B.; Chen, K.; Chen, X. Ga-68-labeled multimeric RGD peptides for microPET imaging of integrin α(v)β(3) expression Eur. J. Nucl. Med. Mol. Imaging 2008, 35 (6) 1100-1108
176. Jamar, F.; Barone, R.; Mathieu, I.; Walrand, S.; Labar, D.; Carlier, P.; de Camps, J.; Schran, H.; Chen, T.; Smith, M. C.; Bouterfa, H.; Valkema, R.; Krenning, E. P.; Kvols, L. K.; Pauwels, S. Y-86-DOTA(0)-D-Phe(1)-Tyr(3)- octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion Eur. J. Nucl. Med. Mol. Imaging 2003, 30 (4) 510-518
177. Rosch, F.; Herzog, H.; Stolz, B.; Brockmann, J.; Kohle, M.; Muhlensiepen, H.; Marbach, P.; Muller-Gartner, H. W. Uptake kinetics of the somatostatin receptor ligand Y-86 DOTA-DPhe(1)-Tyr(3)-octreotide (Y-86 SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the Y-90-labelled analogue Eur. J. Nucl. Med. 1999, 26 (4) 358-366
178. Boerman, O. C.; van Schaijk, F. G.; Oyen, W. J. G.; Corstens, F. H. M. Pretargeted radioimmunotherapy of cancer: Progress step by step J. Nucl. Med. 2003, 44 (3) 400-411
179. Knox, S. J.; Goris, M. L.; Tempero, M.; Weiden, P. L.; Gentner, L.; Breitz, H.; Adams, G. P.; Axworthy, D.; Gaffigan, S.; Bryan, K.; Fisher, D. R.; Colcher, D.; Horak, I. D.; Weiner, L. M. Phase II trial of yttrium-90-DOTA- biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer Clin. Cancer Res. 2000, 6 (2) 406-414
180. 177Lu for targeted radioimmunotherapy Bioconjugate Chem. 2012, 23 (9) 1775-1782
181. Miao, Y.; Gallazzi, F.; Guo, H.; Quinn, T. P. In-111-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide analogues for melanoma imaging Bioconjugate Chem. 2008, 19 (2) 539-547
182. Kwekkeboom, D. J.; Bakker, W. H.; Kooij, P. P. M.; Konijnenberg, M. W.; Srinivasan, A.; Erion, J. L.; Schmidt, M. A.; Bugaj, J. L.; de Jong, M.; Krenning, E. P. Lu-177-DOTA(0),Tyr(3) octreotate: comparison with In-111-DTPA(0) octreotide in patients Eur. J. Nucl. Med. 2001, 28 (9) 1319-1325
183. Perols, A.; Honarvar, H.; Strand, J.; Selvaraju, R.; Orlova, A.; Karlstrom, A. E.; Tolmachev, V. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules Bioconjugate Chem. 2012, 23 (8) 1661-1670
184. Brucke, T.; Podreka, I.; Angelberger, P.; Wenger, S.; Topitz, A.; Kufferle, B.; Muller, C.; Deecke, L. Dopamine-D2 receptor imaging with SPECT- Studies in different neuropsychiatric disorders J. Cereb. Blood Flow Metab. 1991, 11 (2) 220-228
185. Sundaresan, G.; Yazaki, P. J.; Shively, J. E.; Finn, R. D.; Larson, S. M.; Raubitschek, A. A.; Williams, L. E.; Chatziioannou, A. F.; Gambhir, S. S.; Wu, A. M. I-124-labeled engineered Anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice J. Nucl. Med. 2003, 44 (12) 1962-1969
186. Wang, Y. M.; Klunk, W. E.; Debnath, M. L.; Huang, G. F.; Holt, D. P.; Shao, L.; Mathis, C. A. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease J. Mol. Neurosci. 2004, 24 (1) 55-62
187. Menges, M.; Uder, M.; Kuwert, T.; Schmidt, D. I-131 SPECT/CT in the follow-up of patients with differentiated thyroid carcinoma Clin. Nucl. Med. 2012, 37 (6) 555-560
188. Soundararajan, A.; Bao, A.; Phillips, W. T.; Perez, R., III; Goins, B. A. [(186)Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model Nucl. Med. Biol. 2009, 36 (5) 515-524
189. Bayly, S. R.; Fisher, C. L.; Storr, T.; Adam, M. J.; Orvig, C. Carbohydrate conjugates for molecular imaging and radiotherapy: Tc-99m(I) and Re-186(I) tricarbonyl complexes of N-(2′-hydroxybenzyl)-2-amino-2-deoxy-D- glucose Bioconjugate Chem. 2004, 15 (4) 923-926
190. Hashimoto, K.; Yoshihara, K. Rhenium complexes labeled with Re-186,Re-188 for nuclear medicine Technetium Rhenium 1996, 176, 275-291
191. Chen, L. C.; Chang, C. H.; Yu, C. Y.; Chang, Y. J.; Hsu, W. C.; Ho, C. L.; Yeh, C. H.; Luo, T. Y.; Lee, T. W.; Ting, G. Biodistribution, pharmacokinetics and imaging of Re-188-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model Nucl. Med. Biol. 2007, 34 (4) 415-423
192. Cao, J. Q.; Wang, Y. X.; Yu, J. F.; Xia, J. Y.; Zhang, C. F.; Yin, D. Z.; Hafeli, U. O. Preparation and radiolabeling of surface-modified magnetic nanoparticles with rhenium-188 for magnetic targeted radiotherapy J. Magn. Magn. Mater. 2004, 277 (1-2) 165-174
193. Knapp, F. F. Rhenium-188-A generator-derived radioisotope for cancer therapy Cancer Biother. Radiopharm. 1998, 13 (5) 337-349
194. Matsuura, N.; Rowlands, J. A. Towards new functional nanostructures for medical imaging Med. Phys. 2008, 35 (10) 4474-4487
195. Notni, J.; Pohle, K.; Wester, H. J. Comparative gallium-68 labeling of TRAP-, NOTA-, and DOTA-peptides: practical consequences for the future of gallium-68-PET EJNMMI Res. 2012, 2 (1) 28
196. Cooper, M. S.; Ma, M. T.; Sunassee, K.; Shaw, K. P.; Williams, J. D.; Paul, R. L.; Donnelly, P. S.; Blower, P. J. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability Bioconjugate Chem. 2012, 23 (5) 1029-1039
197. Biddlecombe, G. B.; Rogers, B. E.; de Visser, M.; Parry, J. J.; de Jong, M.; Erion, J. L.; Lewis, J. S. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)- bombesin(1-14) Bioconjugate Chem. 2007, 18 (3) 724-730
198. Cherry, S. R. Multimodality in vivo imaging systems: Twice the power or double the trouble? Annu. Rev. Biomed. Eng. 2006, 8, 35-62
199. Pichler, B. J.; Wehrl, H. F.; Judenhofer, M. S. Latest advances in molecular imaging instrumentation J. Nucl. Med. 2008, 49 (Suppl. 2) 5S-23S
200. Judenhofer, M. S.; Wehrl, H. F.; Newport, D. F.; Catana, C.; Siegel, S. B.; Becker, M.; Thielscher, A.; Kneilling, M.; Lichy, M. P.; Eichner, M.; Klingel, K.; Reischl, G.; Widmaier, S.; Rocken, M.; Nutt, R. E.; Machulla, H. J.; Uludag, K.; Cherry, S. R.; Claussen, C. D.; Pichler, B. J. Simultaneous PET-MRI: a new approach for functional and morphological imaging Nat. Med. 2008, 14 (4) 459-465
201. Frullano, L.; Catana, C.; Benner, T.; Sherry, A. D.; Caravan, P. Bimodal MR-PET agent for quantitative pH imaging Angew. Chem., Int. Ed. Engl. 2010, 49 (13) 2382-2384
202. Mukhopadhyay, A.; Bueso-Ramos, C.; Chatterjee, D.; Pantazis, P.; Aggarwal, B. B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines Oncogene 2001, 20 (52) 7597-7609
203. Dorai, T.; Cao, Y. C.; Dorai, B.; Buttyan, R.; Katz, A. E. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo Prostate 2001, 47 (4) 293-303
204. Dorai, T.; Gehani, N.; Katz, A. Therapeutic potential of curcumin in human prostate cancer-I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells Prostate Cancer Prostat. Dis. 2000, 3 (2) 84-93
205. Dorai, T.; Gehani, N.; Katz, A. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein Mol. Urol. 2000, 4 (1) 1-6
206. Davis, J. N.; Muqim, N.; Bhuiyan, M.; Kucuk, O.; Pienta, K. J.; Sarkar, F. H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells Int. J. Oncol. 2000, 16 (6) 1091-1097
207. Hsieh, T. C.; Huang, Y. C.; Wu, J. M. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro Carcinogenesis 2011, 32 (1) 93-101
208. Abderrezak, A.; Bourassa, P.; Mandeville, J. S.; Sedaghat-Herati, R.; Tajmir-Riahi, H. A. Dendrimers bind antioxidant polyphenols and cisplatin drug PLoS One 2012, 7 (3) e33102
209. Morgan, M. T.; Carnahan, M. A.; Immoos, C. E.; Ribeiro, A. A.; Finkelstein, S.; Lee, S. J.; Grinstaff, M. W. Dendritic Molecular Capsules for Hydrophobic Compounds J. Am. Chem. Soc. 2003, 125 (50) 15485-15489
210. Morgan, M. T.; Nakanishi, Y.; Kroll, D. J.; Griset, A. P.; Carnahan, M. A.; Wathier, M.; Oberlies, N. H.; Manikumar, G.; Wani, M. C.; Grinstaff, M. W. Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro Cancer Res. 2006, 66 (24) 11913-11921
211. Gurdag, S.; Khandare, J.; Stapels, S.; Matherly, L. H.; Kannan, R. M. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines Bioconjugate Chem. 2006, 17 (2) 275-283
212. Malik, N.; Evagorou, E. G.; Duncan, R. Dendrimer-platinate: a novel approach to cancer chemotherapy Anticancer Drugs 1999, 10 (8) 767-776
213. Chauhan, A. S.; Sridevi, S.; Chalasani, K. B.; Jain, A. K.; Jain, S. K.; Jain, N. K.; Diwan, P. V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin J. Controlled Release 2003, 90 (3) 335-343
214. Khandare, J. J.; Jayant, S.; Singh, A.; Chandna, P.; Wang, Y.; Vorsa, N.; Minko, T. Dendrimer versus linear conjugate: Influence of polymeric architecture on the delivery and anticancer effect of paclitaxel Bioconjugate Chem. 2006, 17 (6) 1464-72
215. Kochanek, S.; Gansbacher, B. Prostate cancer gene therapy: attempts to innovate Human Gene Ther. 2010, 21 (7) 791
216. Kay, M. A.; Glorioso, J. C.; Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics Nat. Med. 2001, 7 (1) 33-40
217. Merdan, T.; Kopecek, J.; Kissel, T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer Adv. Drug Delivery Rev. 2002, 54 (5) 715-758
218. Chen, Y.; Wang, G.; Kong, D.; Zhang, Z.; Yang, K.; Liu, R.; Zhao, W.; Xu, Y. Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer Mol. Carcinog. 2011, 10.1002/mc.21850
219. Arima, H.; Yoshimatsu, A.; Ikeda, H.; Ohyama, A.; Motoyama, K.; Higashi, T.; Tsuchiya, A.; Niidome, T.; Katayama, Y.; Hattori, K.; Takeuchi, T. Folate-PEG-appended dendrimer conjugate with α-cyclodextrin as a novel cancer cell-Selective siRNA delivery carrier Mol. Pharmaceutics 2012, 9 (9) 2591-2604
220. Zhang, Y.; Zhou, C.; Kwak, K. J.; Wang, X.; Yung, B.; Lee, L. J.; Wang, Y.; Wang, P. G.; Lee, R. J. Efficient siRNA delivery using a polyamidoamine dendrimer with a modified pentaerythritol core Pharm. Res. 2012, 29 (6) 1627-1636
221. Liu, X.; Liu, C.; Laurini, E.; Posocco, P.; Pricl, S.; Qu, F.; Rocchi, P.; Peng, L. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer Mol. Pharmaceutics 2012, 9 (3) 470-481
222. Jensen, L. B.; Pavan, G. M.; Kasimova, M. R.; Rutherford, S.; Danani, A.; Nielsen, H. M.; Foged, C. Elucidating the molecular mechanism of PAMAM-siRNA dendriplex self-assembly: effect of dendrimer charge density Int. J. Pharmaceutics 2011, 416 (2) 410-418
223. Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen Cancer Res. 2002, 62 (14) 4029-4033
224. Liu, X. X.; Rocchi, P.; Qu, F. Q.; Zheng, S. Q.; Liang, Z. C.; Gleave, M.; Iovanna, J.; Peng, L. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells ChemMedChem 2009, 4 (8) 1302-1310
225. Rocchi, P.; So, A.; Kojima, S.; Signaevsky, M.; Beraldi, E.; Fazli, L.; Hurtado-Coll, A.; Yamanaka, K.; Gleave, M. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer Cancer Res. 2004, 64 (18) 6595-6602
226. Rocchi, P.; Beraldi, E.; Ettinger, S.; Fazli, L.; Vessella, R. L.; Nelson, C.; Gleave, M. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis Cancer Res. 2005, 65 (23) 11083-11093
227. Chen, K.; Rajewsky, N. The evolution of gene regulation by transcription factors and microRNAs Nat. Rev. Genet. 2007, 8 (2) 93-103
228. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004, 116 (2) 281-297
229. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D'Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; Bartucci, M.; Muto, G.; Peschle, C.; De Maria, R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities Nat. Med. 2008, 14 (11) 1271-1277
230. Toi, M.; Horiguchi, K.; Bando, H.; Saji, S.; Chow, L. W. Trastuzumab: updates and future issues Cancer Chemother. Pharmacol. 2005, 56 (Suppl. 1) 94-99
231. Vieweg, J.; Jackson, A. Antigenic targets for renal cell carcinoma immunotherapy Exp. Opin. Biol. Ther. 2004, 4 (11) 1791-1801
232. Vieweg, J.; Dannull, J. Technology Insight: vaccine therapy for prostate cancer Nat. Clin. Pract. Urol. 2005, 2 (1) 44-51
233. Drake, C. G.; Doody, A. D.; Mihalyo, M. A.; Huang, C. T.; Kelleher, E.; Ravi, S.; Hipkiss, E. L.; Flies, D. B.; Kennedy, E. P.; Long, M.; McGary, P. W.; Coryell, L.; Nelson, W. G.; Pardoll, D. M.; Adler, A. J. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen Cancer Cell 2005, 7 (3) 239-249
234. Heegaard, P. M.; Boas, U.; Sorensen, N. S. Dendrimers for vaccine and immunostimulatory uses. A review Bioconjugate Chem. 2010, 21 (3) 405-418
235. Pan, M. H.; Gao, D. W.; Feng, J.; He, J.; Seo, Y.; Tedesco, J.; Wolodzko, J. G.; Hasegawa, B. H.; Franc, B. L. Biodistributions of 177Lu- and 111In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of 111In-7E11 as a pre-therapeutic agent for 177Lu-7E11 radioimmunotherapy Mol. Imaging Biol. 2009, 11 (3) 159-166
236. Vallabhajosula, S.; Kuji, I.; Hamacher, K. A.; Konishi, S.; Kostakoglu, L.; Kothari, P. A.; Milowski, M. I.; Nanus, D. M.; Bander, N. H.; Goldsmith, S. J. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J. Nucl. Med. 2005, 46 (4) 634-641
237. Davies, A. J. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab Oncogene 2007, 26 (25) 3614-3628
238. Phillips, W. T.; Goins, B.; Bao, A.; Vargas, D.; Guttierez, J. E.; Trevino, A.; Miller, J. R.; Henry, J.; Zuniga, R.; Vecil, G.; Brenner, A. J. Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastoma Neuro-Oncology 2012, 14 (4) 416-425
239. Liang, S.; Wang, Y.; Yu, J.; Zhang, C.; Xia, J.; Yin, D. Surface modified superparamagnetic iron oxide nanoparticles: as a new carrier for bio-magnetically targeted therapy J. Mater. Sci.: Mater. Med. 2007, 18 (12) 2297-2302
240. Liang, S.; Wang, Y.; Zhang, C.; Liu, X.; Liu, Z.; Xu, R.; Yin, D. Synthesis of amino-modified magnetite nanoparticles coated with Hepama-1 and radiolabeled with Re-188 for bio-magnetically targeted radiotherapy J. Radioanal. Nucl. Chem. 2006, 269 (1) 3-7
241. Chen, L. C.; Chang, C. H.; Yu, C. Y.; Chang, Y. J.; Hsu, W. C.; Ho, C. L.; Yeh, C. H.; Luo, T. Y.; Lee, T. W.; Ting, G. Biodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model Nucl. Med. Biol. 2007, 34 (4) 415-423
242. Chen, L. C.; Chang, C. H.; Yu, C. Y.; Chang, Y. J.; Wu, Y. H.; Lee, W. C.; Yeh, C. H.; Lee, T. W.; Ting, G. Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice model Nucl. Med. Biol. 2008, 35 (8) 883-893
243. 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing mice Anticancer Res. 2010, 30 (1) 65-72
244. Chang, C. H.; Stabin, M. G.; Chang, Y. J.; Chen, L. C.; Chen, M. H.; Chang, T. J.; Lee, T. W.; Ting, G. Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy Cancer Biother. Radiopharm. 2008, 23 (6) 749-758
245. 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model Anticancer Res. 2007, 27 (4B) 2217-2225
246. 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor model Nucl. Med. Biol. 2010, 37 (1) 95-104
247. Wilson, J. D.; Broaddus, W. C.; Dorn, H. C.; Fatouros, P. P.; Chalfant, C. E.; Shultz, M. D. Metallofullerene-Nanoplatform-Delivered Interstitial Brachytherapy Improved Survival in a Murine Model of Glioblastoma Multiforme Bioconjugate Chem. 2012, 23 (9) 1873-1880
248. Zhou, C.; Hao, G.; Thomas, P.; Liu, J.; Yu, M.; Sun, S.; Oz, O. K.; Sun, X.; Zheng, J. Near-infrared emitting radioactive gold nanoparticles with molecular pharmacokinetics Angew. Chem., Int. Ed. Engl. 2012, 51 (40) 10118-10122
249. Zhou, C.; Long, M.; Qin, Y.; Sun, X.; Zheng, J. Luminescent gold nanoparticles with efficient renal clearance Angew. Chem., Int. Ed. Engl. 2011, 50 (14) 3168-3172
250. 177Lu for targeted radioimmunotherapy Bioconjugate Chem. 2012, 23 (9) 1775-1782
251. Perols, A.; Honarvar, H.; Strand, J.; Selvaraju, R.; Orlova, A.; Eriksson Karlstrom, A.; Tolmachev, V. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules Bioconjugate Chem. 2012, 23 (8) 1661-1670
252. Guo, H.; Yang, J.; Shenoy, N.; Miao, Y. Gallium-67-labeled lactam bridge-cyclized α-melanocyte stimulating hormone peptide for primary and metastatic melanoma imaging Bioconjugate Chem. 2009, 20 (12) 2356-2363
253. Dhar, S.; Gu, F. X.; Langer, R.; Farokhzad, O. C.; Lippard, S. J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (45) 17356-17361